Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13719066 | 1.00 | IP6K1 (0.42) | IP6K1IP6K2APPNFE2L2CYP4F2 | |
| SCHEMBL24150774 | 0.83 | IP6K1 (0.43) | IP6K1IP6K2APPNFE2L2CYP4F2 | |
| SCHEMBL26820204 | 0.82 | IAPP (0.54) | APPNFE2L2SMARCA2SMARCA4PTGS1 | |
| SCHEMBL25075381 | 0.82 | IAPP (0.54) | APPNFE2L2SMARCA2SMARCA4PTGS1 | |
| SCHEMBL2134058 | 0.80 | KDM4E (0.53) | APPNFE2L2ALOX5LMNARAB9A | |
| SCHEMBL2134056 | 0.80 | KDM4E (0.53) | APPNFE2L2ALOX5LMNARAB9A | |
| SCHEMBL24738883 | 0.78 | TTR (0.58) | IP6K1IP6K2APPNFE2L2SMARCA2 | |
| SCHEMBL29879436 | 0.78 | TTR (0.58) | IP6K1IP6K2APPNFE2L2SMARCA2 | |
| SCHEMBL29136998 | 0.78 | TTR (0.58) | IP6K1IP6K2APPNFE2L2SMARCA2 | |
| SCHEMBL24150009 | 0.76 | JUN (0.62) | IP6K1IP6K2NFE2L2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050245517-A1 | 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones | SKOLNICK PHIL | 2005-11-03 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | IP6K1 373/4885IP6K2 378/4885APP 2668/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | IP6K1 312/4885IP6K2 276/4885APP 3084/4885 |
| US-20050245517-A1 | 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones | HTR1A, HTR2B, HTR3B | IP6K1 2434/4885IP6K2 2274/4885APP 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.